JPMorgan Chase & Co. set a €90.00 ($104.65) price target on Merck KGaA (FRA:MRK) in a report released on Wednesday. The brokerage currently has a neutral rating on the healthcare company’s stock.

MRK has been the topic of several other reports. Barclays set a €70.00 ($81.40) price objective on shares of Merck KGaA and gave the company a sell rating in a research note on Friday, August 24th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the company a buy rating in a research note on Tuesday, July 3rd. Berenberg Bank set a €102.00 ($118.60) price objective on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, August 30th. Goldman Sachs Group set a €92.00 ($106.98) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Wednesday, September 12th. Finally, Societe Generale set a €92.00 ($106.98) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of €98.81 ($114.89).

Shares of MRK opened at €86.26 ($100.30) on Wednesday. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.